Title:
Ph3 Study of SRT vs STaRT with gamma tile for mBrain Tumors
View
Description: A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors (GTM-102)
Indication:
Brain Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
View
Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
View
Description: A Phase III Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
View
Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)
Indication:
Breast Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 robotic Hysterectomy ROCC
View
Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)
Indication:
Cervical Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Study of MK2870 Monotherapy in participants with Endometrial Cancer
View
Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
Indication:
Endometrial Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Study of MK2870 Monotherapy in participants with Endometrial Cancer
View
Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 Study of MK2870 Monotherapy in participants with Endometrial Cancer
View
Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Houston Willowbrook
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tomball
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph3 study to evaluate to treat patients with HNSCC
View
Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 study of pembro in HNSCC in the disease without curative therapy available
View
Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Willowbrook
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Tomball
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Willowbrook
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Tomball
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
View
Description: SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
View
Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
View
Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
View
Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
View
Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
View
Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
View
Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Willowbrook
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Tomball
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC
View
Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)
View
Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)
Indication:
Lung Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
View
Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Beaumont
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Houston Memorial City
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Sugar Land
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-The Woodlands
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Deke Slayton Cancer Center
Phase: III
Title:
Ph3 study of MK-5684 versus alternative NHA in mCRPC
View
Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)
Indication:
Prostate Cancer
Location:
Texas Oncology-Houston Southeast
Phase: III
Title:
Ph3 Study of SRT vs STaRT with gamma tile for mBrain Tumors
View
Description: A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors (GTM-102)
Indication:
Solid Tumors
Location:
Texas Oncology-The Woodlands
Phase: III